IXICO plc Notice of half year results
May 07 2024 - 2:00AM
RNS Regulatory News
RNS Number : 2578N
IXICO plc
07 May 2024
7 May 2024
IXICO
plc
("IXICO"
or the "Company")
Notice of half-year results and investor
presentation via Investor Meet Company.
IXICO PLC is pleased to announce that it will
release its half-year results on Tuesday 21 May
2024.
Giulio Cerroni and Grant Nash will provide a
live presentation relating to these results and a broader Company
update via Investor Meet Company on 21 May 2024, 16:30
BST.
The presentation is open to all existing and
potential shareholders. Questions can be submitted pre-event via
your Investor Meet Company dashboard up until 20 May 2024, 09:00
BST, or at any time during the live presentation.
Investors can sign up to Investor Meet Company
for free and add to meet IXICO PLC via:
https://www.investormeetcompany.com/ixico-plc/register-investor
Investors who already follow IXICO
PLC on the Investor Meet Company platform will automatically be
invited.
For
further information please contact:
|
IXICO plc
|
+44 (0) 20 3763 7499
|
|
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial
Officer
|
|
|
|
|
|
Cavendish Capital Markets Limited (Nominated adviser and sole
broker)
|
+44 (0) 20 7220 0500
|
|
Giles Balleny / Dan Hodkinson
(Corporate Finance)
|
|
|
|
Nigel Birks/Harriet Ward (Corporate
Broking)
|
|
|
|
Michael F Johnson / Tamar Cranford
Smith (Sales)
|
|
|
|
|
|
|
|
|
|
| |
About
IXICO
IXICO is dedicated to
delivering insights in neuroscience to help transform the
advancement of investigational therapies for neurological diseases,
such as Huntington's disease, Parkinson's disease and Alzheimer's
disease. The Company's purpose is to advance medicine and human
health by turning data into clinically meaningful information,
providing valuable new insights in neuroscience by supporting
pharmaceutical companies across all phases of CNS clinical
research. IXICO's goal is to be a leading advocate of
artificial intelligence in medical image analysis.
IXICO has developed and
deployed breakthrough data analytics, at scale, through its remote
access technology platform, to improve the return on investment in
drug development and reduce risk and uncertainty in clinical trials
for the Company's pharmaceutical clients.
More information is available
on www.IXICO.com and follow us on Twitter @IXICOnews
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NORBLGDUSBGDGSX
Ixico (LSE:IXI)
Historical Stock Chart
From Jan 2025 to Feb 2025
Ixico (LSE:IXI)
Historical Stock Chart
From Feb 2024 to Feb 2025
